CHRS 10-Q: SEC filing
Coherus Oncology
Filed with the SEC on · accession 0001104659-26-124572
CHRS filed a 10-Q (quarterly report) with the SEC on Nov 9, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.
Summary of the filing
Coherus Oncology filed its Q3 2026 Form 10-Q, reporting quarterly financial results including revenue from its Toripalimab (Loqtorzi) product and detailing recent financing activities including a public offering and a new 2031 term loan tranche.
Key details
✦ Ask GOAX AI about this filing — what it means for CHRS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CHRS?
Click hereFrequently asked questions
What did CHRS file with the SEC on Nov 9, 2026?
CHRS filed a 10-Q (SEC filing). Coherus Oncology filed its Q3 2026 Form 10-Q, reporting quarterly financial results including revenue from its Toripalimab (Loqtorzi) product and detailing recent financing activities including a public offering and a new 2031 term loan tranche.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Other CHRS SEC filings
- 8-K · SEC filingOct 29, 2026
- 8-K · Secondary offeringAug 28, 2026
- 8-K · Material agreementAug 17, 2026
- 8-K · Dividend changeAug 17, 2026
- 8-K · SEC filingAug 5, 2026
- 10-Q · SEC filingAug 5, 2026
- 8-K · Auditor changeJun 15, 2026
- 8-K · SEC filingJun 1, 2026
- 8-K · SEC filingMay 11, 2026
- 10-Q · SEC filingMay 11, 2026
Get alerts when CHRS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days